BPC-157 TB-500 FAQ: The Wolverine Blend, Answered

Definitions

BPC-157 TB-500 questions cluster into a few groups — what the blend is, how the two peptides work, whether they help specific injuries, how the dosing literature reads, and where the pair stands legally. The answers below are the same ones placed on the topic pages, gathered here as the index, and each quantitative claim is cited ^[1][9].

What is the Wolverine peptide blend?

A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity or an approved product, and no standardized composition or ratio is clinically validated ^[9].

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to residues 17-23, the actin-binding motif, of Thymosin Beta-4 ^[3][5]. The "Wolverine" blend pairs the two.

What is the BPC-157 and TB-500 blend used for in research?

In animal models the two constituents are studied separately for tissue repair: BPC-157 for tendon, ligament and muscle healing ^[1]; TB-500 / Thymosin Beta-4 for cell migration, wound re-epithelialization and angiogenesis ^[4]. The combination itself has no controlled study ^[6].

What does TB-500 stand for and how does it relate to Thymosin Beta-4?

TB-500 is the synthetic N-acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17-23 — the actin-binding motif — of the 43-residue protein Thymosin Beta-4 ^[5]. Most efficacy data attributed to "TB-500" were generated with the full-length protein rather than the 7-mer, a distinction the literature stresses ^[4][5].

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid pentadecapeptide (~1419.5 Da) from a human gastric-juice protein, acting on VEGFR2/eNOS angiogenic and growth-hormone-receptor pathways ^[2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ, ~889 Da) of Thymosin Beta-4 that sequesters G-actin to regulate cell migration ^[3].

Mechanism and combination

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) while TB-500 supplies an intracellular actin-sequestration signal driving cell migration ^[2][3]. This synergy is a theoretical extrapolation from two non-overlapping mechanisms, not a finding from a controlled combination study ^[6].

How does TB-500 work (actin / Thymosin Beta-4)?

TB-500's LKKTETQ motif binds monomeric G-actin one-to-one. X-ray crystallography of a gelsolin-domain-1-Thymosin-Beta-4 hybrid bound to actin established that Thymosin Beta-4 sequesters the actin monomer by capping both ends, preventing polymerization — the cytoskeletal basis for its cell-migration role ^[3].

How does BPC-157 work compared to TB-500?

They act through largely non-overlapping pathways. BPC-157 is a local cytoprotective and pro-angiogenic signal (VEGFR2 up-regulation leading to Akt then eNOS) while TB-500 is an intracellular actin-sequestration signal (G-actin binding via LKKTETQ) regulating cytoskeletal dynamics and migration ^[2][3].

Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

In research models, yes — by distinct routes. BPC-157 up-regulates VEGFR2 and promotes its internalization with downstream VEGFR2-Akt-eNOS signaling (increased vessel density, faster blood-flow recovery in ischemic muscle) ^[2]; the consolidated Thymosin Beta-4 review describes promotion of angiogenesis alongside cell migration ^[4]. These are single-compound findings, not a combination study.

Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No. No peer-reviewed study defines a synergy ratio, dose or endpoint for the two given together. A 2025 systematic review of BPC-157 (36 studies, only 1 human) makes no mention of TB-500 or combination use; the synergy claim is an extrapolation ^[6].

Evidence and efficacy

What is the latest research on BPC-157 and TB-500?

The most recent and defensible literature is review-level: a 2025 systematic review of BPC-157 in orthopaedic sports medicine (36 studies, only 1 human, "no clinical safety data," no TB-500 or combination mention) ^[6]; a 2025 narrative review calling BPC-157 investigational with only three pilot human studies ^[7]; and a 2026 Sports Medicine review noting unapproved musculoskeletal peptides show animal-model promise but scarce human safety data ^[8].

Are there human clinical trials on the BPC-157 + TB-500 combination?

No. There are no controlled clinical trials of the combination. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies ^[7], and "TB-500" human data are for full-length Thymosin Beta-4, not the heptapeptide ^[9]. Recent reviews call BPC-157 investigational ^[7].

Does the BPC-157 TB-500 blend help tendon and ligament injuries?

The evidence is animal-model and single-compound. BPC-157 accelerated healing of a transected rat Achilles tendon across biomechanical, functional and microscopic measures and stimulated tendocyte growth in vitro ^[1]; the consolidated Thymosin Beta-4 review describes cell migration and anti-scarring activity ^[4]. No human or combination tendon trial exists ^[6].

Does BPC-157 and TB-500 help muscle tears and recovery?

Only in animal models, separately. BPC-157 tendon and tendocyte data ^[1] and Thymosin Beta-4's migration and cell-mobilization activity are the basis of the recovery rationale; the consolidated Thymosin Beta-4 review describes cell migration, reduced scar-forming myofibroblasts and angiogenesis ^[4]. Human combination recovery data do not exist ^[9].

Does the BPC-157 TB-500 blend help wound healing?

In animal models, the TB-500 side has wound-repair support: the consolidated Thymosin Beta-4 review describes actin-driven cell migration, re-epithelialization, reduced scar-forming myofibroblasts, anti-inflammatory signaling and angiogenesis ^[4]. These are single-compound, largely animal-model findings; no human combination wound trial exists ^[9].

Dosage and handling

What is the half-life of BPC-157 and TB-500?

No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157 elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study; human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide ^[9].

How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated; a common practice is to reconstitute them separately or in a shared vial. Product identity, purity and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed ^[9]. This describes research handling, not a human-use instruction.

How often should you inject BPC-157 and TB-500?

There is no validated dose or schedule for the blend. Community "loading then maintenance" protocols and fixed-ratio vials (e.g. 10 mg plus 10 mg) have no basis in controlled human trials ^[9]. The underlying rodent studies used per-body-weight dosing that does not translate to a human regimen ^[1]; framing stays research-only.

How do you cycle BPC-157 and TB-500?

No validated cycling protocol exists; community "loading then maintenance" schedules have no controlled-trial basis. A rat embolic-stroke study even found Thymosin Beta-4 dosing non-monotonic (18 mg/kg gave no benefit), undermining "more is better" loading rationales ^[4]. Any cycle described in forums is not validated dosing.

Safety and legal status

What are the side effects of BPC-157 and TB-500?

There is no controlled human safety dataset for the blend. A 2025 BPC-157 systematic review explicitly found "no clinical safety data" ^[6]; 2025-2026 reviews note that unapproved musculoskeletal peptides can carry potential for serious harm and operate largely outside regulatory oversight ^[7][8]. Long-term human safety of the combination is unknown ^[9].

Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 (TB-500's parent protein) is overexpressed in several cancers and has been implicated in metastasis and tumor angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression ^[4]. This is a flagged safety concern, not a demonstrated effect of the blend in humans — there are no human outcome data ^[9].

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use and the blend has no approved indication ^[11]. Both are prohibited by WADA — BPC-157 under the S0 non-approved-substances category and TB-500 / Thymosin Beta-4 under prohibited peptide and tissue-repair categories ^[5]. As it stands today, FDA placed both in Category 2 for 503A compounding (effective September 29, 2023), pending further evaluation ^[11].

Is Wolverine legal?

Neither constituent is an FDA-approved medicine and both are WADA-prohibited; status depends on jurisdiction and context (research-use versus human-use) ^[5][11]. As the record stands today, both BPC-157 and TB-500 are in FDA Category 2 for 503A compounding, and both are on the FDA's July 23-24, 2026 PCAC agenda under review — see the Wolverine legal status and 503A compounding page ^[10][11].

Can you get BPC-157 from a compounding pharmacy?

As the record stands today, BPC-157 is in FDA's Category 2 for 503A compounding (effective September 29, 2023), so it is not within FDA's enforcement-discretion policy and access through that route is currently restricted ^[11]. BPC-157 is on the FDA's July 23-24, 2026 PCAC agenda as a candidate for the 503A bulks list — a scheduled review, not a decision ^[10].

What is the FDA 503A status of Wolverine?

Both constituents are FDA 503A Category 2 today — BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — effective with the September 29, 2023 list update ^[11]. Both are on the July 23-24, 2026 PCAC agenda as candidates for the 503A bulks list, under active review with no outcome decided ^[10].